What Is SS-31?
SS-31, also known as Elamipretide, Bendavia or MTP-131, is a mitochondria-targeting synthetic peptide studied for its interaction with the inner mitochondrial membrane.
Unlike metabolic peptides that primarily act through cell-surface hormone receptors, SS-31 research focuses heavily on mitochondrial membrane biology and cardiolipin.
SUNONE supplies research-grade SS-31 for qualified laboratory, analytical and biopharmaceutical research.
SUNONE SS-31 Product Page:
https://52ym.com/products/ss-31/
Why Is Cardiolipin Important?
Cardiolipin is a distinctive phospholipid concentrated in the inner mitochondrial membrane.
It contributes to:
- mitochondrial cristae organization;
- respiratory-chain protein assembly;
- electron transport;
- membrane architecture;
- oxidative phosphorylation.
When cardiolipin structure or remodeling is disrupted, mitochondrial bioenergetics can also become disturbed.
This makes cardiolipin an important target in modern mitochondrial research.
SS-31 Is More Than a Generic “Antioxidant”
SS-31 is frequently described online as an antioxidant peptide.
That description is incomplete.
Earlier research emphasized reduced reactive oxygen species and protection against oxidative stress.
More recent mechanistic work has expanded the model.
SS-31 interacts with cardiolipin-rich regions of the inner mitochondrial membrane and may influence:
- membrane electrostatic properties;
- cristae organization;
- respiratory-chain protein organization;
- oxidative phosphorylation efficiency;
- mitochondrial structural stability.
A more accurate research description is therefore:
cardiolipin-directed mitochondrial peptide
rather than simply:
antioxidant peptide.
Why Does This Distinction Matter?
A conventional antioxidant concept focuses mainly on neutralizing reactive molecules.
SS-31 research asks a broader question:
Can stabilizing mitochondrial membrane organization improve bioenergetic function?
That distinction matters because ROS may sometimes be downstream of mitochondrial structural dysfunction rather than the only problem.
The research framework becomes:
cardiolipin → inner mitochondrial membrane → respiratory organization → bioenergetics → oxidative stress
instead of simply:
ROS → antioxidant.
What Does the Current Clinical Evidence Show?
Elamipretide has been investigated in several mitochondrial and cardiometabolic conditions.
The strongest regulatory development occurred in Barth syndrome, a rare mitochondrial disorder associated with abnormal cardiolipin metabolism.
In September 2025, the U.S. FDA granted accelerated approval to Forzinity (elamipretide) for improving muscle strength in eligible patients with Barth syndrome.
However, this should not be interpreted as proof that SS-31 is clinically effective for every condition involving mitochondrial dysfunction.
Clinical translation remains disease-specific.
SS-31 Research Material Is Not the Same as Forzinity
This distinction is essential.
Forzinity is an FDA-approved pharmaceutical elamipretide product manufactured under controlled pharmaceutical specifications for a defined indication.
SUNONE SS-31 is supplied as Research Grade peptide material.
Approval of Forzinity does not establish:
- pharmaceutical equivalence;
- therapeutic equivalence;
- clinical safety;
- clinical efficacy;
- formulation equivalence
for SUNONE SS-31 or another research-grade material.
Researchers should keep pharmaceutical evidence and research-material specifications separate.
What Do Current SS-31 Reviews Say?
Current online SS-31 reviews are highly mixed.
Positive anecdotal reports sometimes mention:
- increased perceived energy;
- improved stamina;
- improved recovery;
- reduced feelings of fatigue;
- better day-to-day physical capacity.
Negative or neutral reports include:
- no noticeable effect;
- significant fatigue;
- exhaustion;
- brain fog;
- sleep disturbance;
- feeling worse rather than better.
These experiences come from uncontrolled online discussions.
Product identity, analytical purity, underlying medical conditions and other substances are often unknown.
Therefore:
SS-31 reviews are anecdotal search sentiment—not clinical evidence.
They should not be interpreted as reviews of SUNONE Research Grade SS-31.
Why “Better Mitochondria” Is Too Broad a Claim
Mitochondrial dysfunction is not one single biological defect.
Different conditions may involve:
- cardiolipin abnormalities;
- respiratory-chain defects;
- mitochondrial DNA changes;
- impaired mitophagy;
- altered mitochondrial dynamics;
- substrate-utilization problems;
- structural tissue damage.
A peptide acting on inner-membrane organization may therefore produce different outcomes depending on the underlying biological problem.
This helps explain why mechanistic promise does not automatically translate into identical clinical outcomes across diseases.
Why Research-Grade SS-31 Quality Matters
For laboratory studies involving mitochondrial bioenergetics, incorrect material identity can distort experimental interpretation.
Important quality considerations include:
- correct SS-31 molecular identity;
- expected molecular mass;
- HPLC purity;
- peptide-related impurities;
- batch consistency;
- storage conditions;
- analytical documentation.
Researchers should avoid treating the name “Elamipretide” alone as proof that two materials are analytically or pharmaceutically equivalent.
What Should Researchers Check When Choosing an SS-31 Supplier?
SUNONE currently lists:
Product: SS-31
Synonyms: Elamipretide, Bendavia, MTP-131, Szeto-Schiller Peptide 31
CAS: 736992-21-5
Formula: C32H49N9O5
Molecular Weight: 611.78 g/mol
Purity: ≥99% HPLC
Form: Lyophilized Powder
Grade: Research Grade
Storage: 2–8°C, protect from light
Available Packs: 5 mg × 10 vials, 10 mg × 10 vials and 50 mg × 10 vials
Final identity, purity, chemical form, storage requirements and analytical specifications should always be verified against the applicable batch-specific COA, SDS and specification documentation.
View SUNONE Research-Grade SS-31:
https://52ym.com/products/ss-31/
Final Thoughts
A common search asks:
“Is SS-31 a mitochondrial antioxidant?”
A more useful research question is:
“How does SS-31 interaction with cardiolipin influence inner mitochondrial membrane structure and bioenergetics?”
That produces a stronger scientific framework:
SS-31 identity → cardiolipin → inner mitochondrial membrane → cristae organization → respiratory-chain function → bioenergetics → disease-specific evidence.
For laboratories comparing an SS-31 supplier, precise molecular identity and batch-specific analytical documentation should take priority over broad “energy peptide” or “anti-aging peptide” marketing claims.
Disclaimer
This article is provided for scientific, analytical and educational purposes only.
SUNONE SS-31 is intended for research, analytical and manufacturing use only. It is not intended for personal, human or veterinary use, self-administration, diagnosis, treatment, prevention or cure of any disease.
References to mitochondrial function, cardiolipin, oxidative phosphorylation, energy metabolism, fatigue, muscle function or other biological effects describe published scientific and clinical research and do not establish the clinical safety, efficacy or pharmaceutical equivalence of SUNONE Research Grade SS-31.
References to FDA-approved Forzinity concern a specific pharmaceutical elamipretide product and approved Barth syndrome indication. They should not be interpreted as FDA approval of SUNONE SS-31 or any other research-grade SS-31 material.
Online reviews are anecdotal and may involve unidentified products, different formulations, underlying medical conditions, other compounds or uncontrolled variables.
Researchers and purchasers are responsible for reviewing applicable batch-specific COA, HPLC, MS where available, SDS, molecular identity, purity and other analytical documentation and for complying with all applicable laws, regulations and institutional requirements.
Leave a Reply